Tenaya Therapeutics Inc (TNYA)

$1.41 +0.09 (6.82%)
Market Cap 229.80M
Revenue (ttm) 0.00
Net Income (ttm) -111.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,454,500
Avg Vol 3,376,536
Day's Range N/A - N/A
Shares Out 162.98M
Stochastic %K 96%
Beta 3.07
Analysts Strong Sell
Price Target $10.14

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone de...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 825 6990
Address:
171 Oyster Point Boulevard, Suite 500, South San Francisco, United States
Damage111
Damage111 Sep. 20 at 5:31 PM
@Walf0fwaIIstreet I’ve been in this stock $TNYA for a while now and up like 200% I’m reaching out to you to ask what your thoughts are on this stock?
0 · Reply
LakeshaGarcia549
LakeshaGarcia549 Sep. 20 at 1:56 PM
$TNYA Nano-cap with wide spreads. Avoid due to execution risk. No clear technical edge.
1 · Reply
Twittuser1988
Twittuser1988 Sep. 19 at 8:31 PM
$TNYA a lot of shares returned today..could be the reason for the little green
0 · Reply
Groin
Groin Sep. 19 at 8:21 PM
$TNYA Have a nice weekend guys! See you on monday for more 😉
0 · Reply
DCRMIA
DCRMIA Sep. 19 at 7:36 PM
$TNYA there we go🚀🌙
0 · Reply
Stockley_Bulbousberries
Stockley_Bulbousberries Sep. 19 at 4:58 PM
$TNYA
0 · Reply
Zeyyy
Zeyyy Sep. 19 at 2:07 PM
$TNYA GOOOOO UPPPPO BABBEEE!!
0 · Reply
Paulfrench
Paulfrench Sep. 19 at 6:26 AM
Hello $TNYA Now we need to break the resistance at $1.45 before we can consider reaching the 400MA (around $2.2) then $2.5 which should be a significant resistance but all this is conditional on the press release now...we have to wait...
3 · Reply
Paulfrench
Paulfrench Sep. 18 at 5:42 PM
$TNYA actualy, I'm talking nonsense!! We can close wherever we want as long as it's above $1.22...😵‍💫 sorry 😮‍💨
4 · Reply
Paulfrench
Paulfrench Sep. 18 at 4:47 PM
$TNYA we will have an increasing volume today so to have a confirmation of the trend we would have to close at $1.33 otherwise we will have a resistance which will form...I feel a movement just before closing (projection based on my intuition and therefore without rational basis 🤣)
1 · Reply
Latest News on TNYA
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sep 18, 2025, 4:05 PM EDT - 2 days ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:07 PM EDT - 11 days ago

Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 4:05 PM EDT - 18 days ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 31, 2025, 10:15 AM EDT - 20 days ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 8, 2025, 8:00 AM EDT - 6 weeks ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:30 PM EDT - 6 weeks ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Jul 30, 2025, 8:30 AM EDT - 7 weeks ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025, 8:30 AM EDT - 4 months ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Apr 24, 2025, 2:07 PM EDT - 5 months ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 31, 2025, 10:00 AM EDT - 6 months ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 24, 2025, 8:30 AM EDT - 6 months ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 19, 2025, 8:30 AM EDT - 6 months ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 6 months ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Pricing of Public Offering

Mar 3, 2025, 11:19 PM EST - 7 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics Announces Proposed Public Offering

Mar 3, 2025, 4:10 PM EST - 7 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Mar 3, 2025, 8:00 AM EST - 7 months ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Feb 3, 2025, 8:30 AM EST - 8 months ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Jan 13, 2025, 9:16 AM EST - 8 months ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Dec 16, 2024, 4:30 PM EST - 9 months ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 11 months ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Tenaya Therapeutics Announces Research Leadership Updates

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

Jun 18, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

May 2, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 26, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Feb 8, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 26, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 9, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TSBX

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:19 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

May 2, 2023, 7:50 AM EDT - 2 years ago

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

NKTX

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 8, 2023, 4:01 PM EST - 2 years ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Feb 7, 2023, 5:17 PM EST - 2 years ago

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

Dec 7, 2022, 4:30 PM EST - 3 years ago

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

Nov 28, 2022, 8:30 AM EST - 3 years ago

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

Nov 23, 2022, 9:00 AM EST - 3 years ago

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

Tenaya Therapeutics Announces Closing of Public Offering

Nov 21, 2022, 5:45 PM EST - 3 years ago

Tenaya Therapeutics Announces Closing of Public Offering

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

Oct 4, 2022, 8:30 AM EDT - 3 years ago

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

Damage111
Damage111 Sep. 20 at 5:31 PM
@Walf0fwaIIstreet I’ve been in this stock $TNYA for a while now and up like 200% I’m reaching out to you to ask what your thoughts are on this stock?
0 · Reply
LakeshaGarcia549
LakeshaGarcia549 Sep. 20 at 1:56 PM
$TNYA Nano-cap with wide spreads. Avoid due to execution risk. No clear technical edge.
1 · Reply
Twittuser1988
Twittuser1988 Sep. 19 at 8:31 PM
$TNYA a lot of shares returned today..could be the reason for the little green
0 · Reply
Groin
Groin Sep. 19 at 8:21 PM
$TNYA Have a nice weekend guys! See you on monday for more 😉
0 · Reply
DCRMIA
DCRMIA Sep. 19 at 7:36 PM
$TNYA there we go🚀🌙
0 · Reply
Stockley_Bulbousberries
Stockley_Bulbousberries Sep. 19 at 4:58 PM
$TNYA
0 · Reply
Zeyyy
Zeyyy Sep. 19 at 2:07 PM
$TNYA GOOOOO UPPPPO BABBEEE!!
0 · Reply
Paulfrench
Paulfrench Sep. 19 at 6:26 AM
Hello $TNYA Now we need to break the resistance at $1.45 before we can consider reaching the 400MA (around $2.2) then $2.5 which should be a significant resistance but all this is conditional on the press release now...we have to wait...
3 · Reply
Paulfrench
Paulfrench Sep. 18 at 5:42 PM
$TNYA actualy, I'm talking nonsense!! We can close wherever we want as long as it's above $1.22...😵‍💫 sorry 😮‍💨
4 · Reply
Paulfrench
Paulfrench Sep. 18 at 4:47 PM
$TNYA we will have an increasing volume today so to have a confirmation of the trend we would have to close at $1.33 otherwise we will have a resistance which will form...I feel a movement just before closing (projection based on my intuition and therefore without rational basis 🤣)
1 · Reply
DCRMIA
DCRMIA Sep. 18 at 1:54 PM
$TNYA Amazing Divergence in the MACD 1D. There we goooo!✈️
0 · Reply
rickyrasputin69
rickyrasputin69 Sep. 18 at 1:52 PM
$TNYA $3 please, I need a new ass
0 · Reply
devrmoney
devrmoney Sep. 17 at 4:31 PM
$TNYA @Paulfrench , I truly appreciate your insights and analysis. They’ve been very helpful and motivating. Thank You!
1 · Reply
Groin
Groin Sep. 17 at 4:24 PM
$TNYA Will it blow today?
2 · Reply
Sikder95
Sikder95 Sep. 17 at 4:21 PM
$TNYA patience 😊
0 · Reply
Paulfrench
Paulfrench Sep. 17 at 4:20 PM
$TNYA definitely bullish with this RSI divergence that has just emerged...all that's left is to wait... Okay, I'll stop, I feel like I'm making a big deal out of it.🤣🤣...sorry😟
2 · Reply
Paulfrench
Paulfrench Sep. 16 at 8:22 PM
$TNYA Yes! 🤩 We finally have our reversal signal with a discreet VSA divergence that marks the end of the bearish movement and the return of buyers. I'm not saying that price will open at $5 tomorrow, but the uptrend should slowly resume. ✊️
0 · Reply
Groin
Groin Sep. 16 at 4:03 PM
$TNYA Come on Tina!
0 · Reply
Paulfrench
Paulfrench Sep. 16 at 3:52 PM
$TNYA another signal on the 1h chart, now they should appear on the daily🤞😬
1 · Reply
borrow_me_your_shorts
borrow_me_your_shorts Sep. 16 at 11:10 AM
$TNYA getting out at 1.20 — 60% profit. Good luck yall
3 · Reply
DimondTrade100
DimondTrade100 Sep. 16 at 7:23 AM
$TNYA Long-term upside if cost structure improves and revenue diversification occurs
0 · Reply
Paulfrench
Paulfrench Sep. 16 at 6:35 AM
$TNYA Hello fam! A nice candle yesterday with a level at $1.19 that holds, unfortunately it is not a reversal candle (even if there are weak signals on the 1h chart), it is possible that the price will touch $1.13 today. In any case, we need a green candle today with a return of increasing volume and then we will have our signal! 💪 Hold on ! At the end of the week the Kijun sen line should rise and give us more powerful support to start the upward movement ! Have a nice day everybody !
3 · Reply